Bile Acid Metabolism and Signaling
The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Abstract
Bile acids are important physiological agents for intestinal nutrient absorption and biliary secretion of lipids, toxic metabolites, and xenobiotics. Bile acids also are signaling molecules and metabolic regulators that activate nuclear receptors and G protein‐coupled receptor (GPCR) signaling to regulate hepatic lipid, glucose, and energy homeostasis and maintain metabolic homeostasis. Conversion of cholesterol to bile acids is critical for maintaining cholesterol homeostasis and preventing accumulation of cholesterol, triglycerides, and toxic metabolites, and injury in the liver and other organs. Enterohepatic circulation of bile acids from the liver to intestine and back to the liver plays a central role in nutrient absorption and distribution, and metabolic regulation and homeostasis. This physiological process is regulated by a complex membrane transport system in the liver and intestine regulated by nuclear receptors. Toxic bile acids may cause inflammation, apoptosis, and cell death. On the other hand, bile acid‐activated nuclear and GPCR signaling protects against inflammation in liver, intestine, and macrophages. Disorders in bile acid metabolism cause cholestatic liver diseases, dyslipidemia, fatty liver diseases, cardiovascular diseases, and diabetes. Bile acids, bile acid derivatives, and bile acid sequestrants are therapeutic agents for treating chronic liver diseases, obesity, and diabetes in humans. © 2013 American Physiological Society. Compr Physiol 3:1191‐1212, 2013.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–224 of 224
Farnesoid X receptor agonists in biliary tract disease
Fiorucci, S., & Baldelli, F. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328324f87e · Cited by 57
Staels, B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.suppl53.290 · Cited by 54
Sterol 27-hydroxylase Deficiency: A Rare Cause of Xanthomas in Normocholesterolemic Humans
Björkhem, I., & Leitersdorf, E. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00255-1 · Cited by 53
Fang, Y., Studer, E. J., Mitchell, C., Grant, S., Pandak, W. M., Hylemon, P. B., & Dent, P. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032060 · Cited by 53
Ratliff, E. P., Gutierrez, A., & Davis, R. A. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600120-jlr200 · Cited by 52
Drury, J. E., Mindnich, R., & Penning, T. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127779 · Cited by 51
Ferdinandusse, S., Overmars, H., Denis, S., Waterham, H. R., Wanders, R. J. A., & Vreken, P. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32345-2 · Cited by 49
Qiao, L., McKinstry, R. P., Gupta, S., Gilfor, D., Windle, J. J., Hylemon, P. B., Grant, S., Fisher, P. B., & Dent, P. (2002) · Hepatology · doi:10.1053/jhep.2002.33899 · Cited by 47
Hong, C., Bradley, M. N., Rong, X., Wang, X., Wagner, A., Grijalva, V., Castellani, L. W., Salazar, J., Realegeno, S., Boyadjian, R., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m022061 · Cited by 47
Cholesterol 7α-hydroxylase of rat liver: An insulin sensitive enzyme
Subbiah, M. T. R., & Yunker, R. L. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91042-8 · Cited by 46
Song, M., Yu, X., Zhu, G., Chen, J., Zhao, G., & Huang, L. J. (2009) · Vascular Pharmacology · doi:10.1016/j.vph.2009.06.009 · Cited by 45
Counter-Regulatory Role of Bile Acid Activated Receptors in Immunity and Inflammation
Fiorucci, S., Cipriani, S., Mencarelli, A., Renga, B., Distrutti, E., & Baldelli, F. (2010) · Current Molecular Medicine · doi:10.2174/156652410792231312 · Cited by 45
Li, T., & Chiang, J. Y. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.042 · Cited by 44
Self-citationBaker, D. M., Wang, S.-L., Bell, D. J., Drevon, C. A., & Davis, R. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002351200 · Cited by 43
Modulation of Hepatocyte Apoptosis: Cross-talk Between Bile Acids and Nuclear Steroid Receptors
Publisher, B. S. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706778521823 · Cited by 42
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Agellon, B. L., & CHEEMA, K. S. (1997) · Biochemical Journal · doi:10.1042/bj3280393 · Cited by 39
Pandak, W. M., Stravitz, R. T., Lucas, V., Heuman, D. M., & Chiang, J. Y. L. (1996) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1996.270.3.g401 · Cited by 35
Self-citationFXR‐deficiency confers increased susceptibility to torpor
Cariou, B., Bouchaert, E., Abdelkarim, M., Dumont, J., Caron, S., Fruchart, J.-C., Burcelin, R., Kuipers, F., & Staels, B. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.09.064 · Cited by 35
Bertolotti, M., Carulli, L., Concari, M., Martella, P., Loria, P., Tagliafico, E., Ferrari, S., Puppo, M. D., Amati, B., Fabiani, E. D., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.25958 · Cited by 31
Critical role of cholic acid for development of hypercholesterolemia and gallstones in diabetic mice
Wang, J., Gåfvels, M. E., Rudling, M., Murphy, C., Björkhem, I., Einarsson, C., & Eggertsen, G. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.108 · Cited by 27
An alternative pathway of reverse cholesterol transport: The oxysterol 27-hydroxycholesterol
Weingärtner, O., Laufs, U., Böhm, M., & Lütjohann, D. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.015 · Cited by 26
Inborn Errors of Metabolism with Consequences for Bile Acid Biosynthesis: A Minireview
Björkhem, I. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409103629 · Cited by 21
Hansen, M., Sonne, D. P., Mikkelsen, S. U., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001803 · Cited by 9
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“Specifically, the discovery of the bile acid receptors farnesoid X receptor (FXR), Takeda G-coupled protein receptor 5 (TGR5; GPBAR1, M-BAR), pregnane X receptor (PXR), sphingosine-1-phosphate receptor 2 (S1PR2), the muscarinic receptors M2/3, and the vitamin D receptor have established bile acids as multifunctional s…”
BackgroundBile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Metabolomics for Investigating Physiological and Pathophysiological Processes
Wishart, D. S. (2019) · Physiological Reviews · doi:10.1152/physrev.00035.2018 · Cited by 1,212
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
“Recently, therapies targeted to FXR, TGR5, and bile acid metabolism have been developed for treatment of metabolic diseases and cholestatic liver diseases (reviewed in Claudel et al., 2004; Trauner and Halilbasic, 2011; Fiorucci et al., 2012; Porez et al., 2012; Chiang, 2013; Li and Chiang, 2013; Swanson et al., 2013;…”
BackgroundSelf-citation
Metadata
- Authors
- Chiang, J. Y. L.
- Venue
- Comprehensive Physiology
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 3
- Issue
- 3
- Pages
- 1191-1212
- ISSN
- 2040-4603 (ISSN-L)
- OpenAlex
- W4409112878
- Cited by
- 279
- References
- 224
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.